NCT07199257View on ClinicalTrials.gov

A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

May 15, 2027

Study Completion Date

July 31, 2027

Conditions
Allergic Rhinitis, Seasonal
Interventions
BIOLOGICAL

GR1802 injection

Recombinant fully human anti-IL4Rα monoclonal antibody drug.

BIOLOGICAL

Placebo

Placebo

Trial Locations (1)

430000

Zhongnan Hospital of Wuhan university, Wuhan

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY